TN2014000085A1 - Substituted annellated pyrimidine and the use thereof - Google Patents

Substituted annellated pyrimidine and the use thereof

Info

Publication number
TN2014000085A1
TN2014000085A1 TNP2014000085A TN2014000085A TN2014000085A1 TN 2014000085 A1 TN2014000085 A1 TN 2014000085A1 TN P2014000085 A TNP2014000085 A TN P2014000085A TN 2014000085 A TN2014000085 A TN 2014000085A TN 2014000085 A1 TN2014000085 A1 TN 2014000085A1
Authority
TN
Tunisia
Prior art keywords
pyrimidine
prophylaxis
treatment
annellated
diseases
Prior art date
Application number
TNP2014000085A
Inventor
Markus Follmann
Johannes-Peter Stasch
Gorden Redlich
Nils Griebenow
Dieter Lang
Frank Wunder
Niels Lindner
Alexandros Vakalopoulos
Adrian Tersteegen
Walter Hubsch
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/066876 external-priority patent/WO2013030288A1/en
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of TN2014000085A1 publication Critical patent/TN2014000085A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application relates to new substituted annellated pyrimidines, a method for the production thereof, the use thereof in isolation or in combination for the treatment and/or prophylaxis of diseases, and the use thereof to produce medicines for the treatment and/or prophylaxis of diseases, more particularly for the treatment and/or prophylaxis of cardiovascular diseases.
TNP2014000085A 2012-01-11 2014-02-28 Substituted annellated pyrimidine and the use thereof TN2014000085A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE201210200351 DE102012200351A1 (en) 2012-01-11 2012-01-11 New substituted annellated pyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, hypertension, ischemia, vascular disease, renal failure, thromboembolic disorders and fibrotic diseases
PCT/EP2012/066876 WO2013030288A1 (en) 2011-09-02 2012-08-30 Substituted annellated pyrimidine and the use thereof

Publications (1)

Publication Number Publication Date
TN2014000085A1 true TN2014000085A1 (en) 2015-07-01

Family

ID=48652673

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2014000085A TN2014000085A1 (en) 2012-01-11 2014-02-28 Substituted annellated pyrimidine and the use thereof

Country Status (2)

Country Link
DE (1) DE102012200351A1 (en)
TN (1) TN2014000085A1 (en)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314412D0 (en) 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
DE19642255A1 (en) 1996-10-14 1998-04-16 Bayer Ag Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives
DE19834047A1 (en) 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
DE19834044A1 (en) 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
JP4197073B2 (en) 1999-08-27 2008-12-17 株式会社コスモ総合研究所 Deep desulfurization catalyst, method for producing the same, and desulfurization method using the same
DE10220570A1 (en) 2002-05-08 2003-11-20 Bayer Ag Carbamate-substituted pyrazolopyridines
DE10232571A1 (en) 2002-07-18 2004-02-05 Bayer Ag 4-amino substituted pyrimidine derivatives
AU2004236085B2 (en) 2003-05-09 2010-03-25 Asahi Glass Company, Limited Processes for producing 3-substituted 2-chloro-5-fluoropyridine or salt thereof
CN100355732C (en) 2003-11-03 2007-12-19 上海药明康德新药开发有限公司 Preparation of 2-Cl-5-F-nicotinate and nicotonic acid
JP4879988B2 (en) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
NZ582879A (en) 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
JP5409961B2 (en) 2010-05-27 2014-02-05 メルク・シャープ・エンド・ドーム・コーポレイション Soluble guanylate cyclase activator

Also Published As

Publication number Publication date
DE102012200351A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
MX348470B (en) Substituted annellated pyrimidine and the use thereof.
PH12015501703A1 (en) Trifluormethyl-substituted ring-fused pyrimidines and use thereof
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
PH12014502496A1 (en) Bicyclically substituted uracils and the use thereof
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
PH12015500988A1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
IN2014DN08867A (en)
JO3343B1 (en) Novel5-aminotetrahydroquinoline-2-carboxylic acids and their use
MX364486B (en) Pyridazinone-amides derivatives.
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
MX2016000794A (en) High potency pancreatin pharmaceutical compositions.
PH12016500525A1 (en) Substituted phenylalanine derivatives
PH12016500608A1 (en) Cyclic thienouracil-carboxamides and use thereof
AU341611S (en) Dual function wine system
MX2013002261A (en) Substituted n-phenethyltriazoloneacetamides and use thereof.
TN2014000085A1 (en) Substituted annellated pyrimidine and the use thereof
MX2015008454A (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders.
UA74450U (en) Method for treating congenital pneumonias in newborns carried to full time
IN2013CH03945A (en)
AU344478S (en) Inverter
CA142240S (en) Door stop
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof